中国癌症杂志 ›› 2021, Vol. 31 ›› Issue (7): 635-639.doi: 10.19401/j.cnki.1007-3639.2021.07.010

• 综述 • 上一篇    下一篇

小细胞肺癌免疫治疗相关生物标志物研究进展

谢梦青,储香玲,周 娟,苏春霞   

  1. 同济大学附属上海市肺科医院肿瘤科,上海 200433
  • 出版日期:2021-07-30 发布日期:2021-08-04
  • 通信作者: 苏春霞 E-mail: susu_mail@126.com
  • 基金资助:
    国家自然科学基金面上项目(81874036,82072568);上海市科学技术委员会(19411971100);上海市肺科医院面上项目(FKLY20013)。

The advances in immunotherapy biomarkers of small cell lung cancer

XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia   

  1. Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China
  • Published:2021-07-30 Online:2021-08-04
  • Contact: SU Chunxia E-mail: susu_mail@126.com

摘要: 最近30年来小细胞肺癌(small cell lung cancer,SCLC)的治疗手段无明显突破,整体预后也无显著改善。随着免疫治疗时代的开启,免疫检查点抑制剂在SCLC治疗中取得了重大进展,但整体获益仍有限。如何筛选获益人群以进一步提高免疫治疗效果是当下SCLC研究的热点问题之一。通过概述SCLC现状,聚焦SCLC免疫治疗相关生物标志物,综述近年来SCLC免疫治疗标志物研究现状与进展,以期为未来优化免疫治疗策略提供线索和思路。

关键词: 小细胞肺癌, 免疫治疗, 生物标志物

Abstract:  There is no obvious breakthrough in treatment for small cell lung cancer (SCLC) in more than 30 years, and the prognosis has not improved significantly. With the opening of the immune era, immune checkpoint inhibitors have made breakthroughs in SCLC treatment, but the overall benefit population is limited. How to select patients accurately and how to increase the efficacy of immunotherapy are hot topics in SCLC research. Therefore, this article summarized the current status of SCLC with focus on biomarkers related to SCLC immunotherapy, reviewed the progress in the research of immunotherapy markers in recent years, to provide clues and ideas for future immunotherapeutic strategies.

Key words: Small cell lung cancer, Immunotherapy, Biomarkers